Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Authors
Keywords
-
Journal
Diagnostics
Volume 9, Issue 3, Pages 87
Publisher
MDPI AG
Online
2019-08-01
DOI
10.3390/diagnostics9030087
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
- (2019) Jingyan Yi et al. EBioMedicine
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
- (2019) Boussios et al. Diagnostics
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2018) Y. Drew et al. GYNECOLOGIC ONCOLOGY
- Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab
- (2018) P.A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
- (2018) George E. Ronson et al. Nature Communications
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
- (2018) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
- (2018) Shannon Neville Westin et al. JOURNAL OF CLINICAL ONCOLOGY
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Targeting DNA repair and replication stress in the treatment of ovarian cancer
- (2017) Junko Murai International Journal of Clinical Oncology
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
- (2017) Leslie A. Parsels et al. MOLECULAR CANCER RESEARCH
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
- (2015) Ruud van der Noll et al. BRITISH JOURNAL OF CANCER
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
- (2015) S. Kummar et al. CLINICAL CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
- (2014) Jung-Min Lee et al. JNCI-Journal of the National Cancer Institute
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
- (2014) Jaeyoung Lim et al. NEOPLASIA
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- (2012) E Dean et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability
- (2012) R. Kumareswaran et al. JOURNAL OF CELL SCIENCE
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy
- (2012) Farah L. Rehman et al. Cancer Discovery
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients
- (2010) Iwona K. Kolasa et al. CANCER BIOLOGY & THERAPY
- Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
- (2010) N. Chan et al. CANCER RESEARCH
- Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130
- (2010) D. C. Hegan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started